Search Results - "Grabowski, Henry G."

Innovation in the pharmaceutical industry: New estimates of R&D costs by DiMasi, Joseph A., Grabowski, Henry G., Hansen, Ronald W.

“…•R&D costs of 106 new drugs were obtained from a survey of 10 biopharmaceutical firms.•Costs for compounds that were abandoned were linked to costs of approved…”
Get full text

Economics of New Oncology Drug Development by DiMasi, Joseph A, Grabowski, Henry G

“…Review existing studies and provide new results on the development, regulatory, and market aspects of new oncology drug development. We utilized data from the…”
Get full text

The cost of biopharmaceutical R&D: is biotech different? by DiMasi, Joseph A., Grabowski, Henry G.

“…The costs of developing the types of new drugs that have been pursued by traditional pharmaceutical firms have been estimated in a number of studies. However,…”
Get full text

The price of innovation: new estimates of drug development costs by DiMasi, Joseph A, Hansen, Ronald W, Grabowski, Henry G

“…The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate…”
Get full text

Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act by Grabowski, Henry G, Kyle, Margaret, Mortimer, Richard, Long, Genia, Kirson, Noam

“…The evolution of pharmaceutical competition since Congress passed the Hatch-Waxman Act in 1984 raises questions about whether the act's intended balance of…”
Get full text

Economic Return of Clinical Trials Performed Under the Pediatric Exclusivity Program by Li, Jennifer S, Eisenstein, Eric L, Grabowski, Henry G, Reid, Elizabeth D, Mangum, Barry, Schulman, Kevin A, Goldsmith, John V, Murphy, M. Dianne, Califf, Robert M, Benjamin, Daniel K

“…CONTEXT In 1997, Congress authorized the US Food and Drug Administration (FDA) to grant 6-month extensions of marketing rights through the Pediatric…”
Get full text

Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future by Grabowski, Henry G, Guha, Rahul, Salgado, Maria

“…In March 2010 Congress established an abbreviated Food and Drug Administration approval pathway for biosimilars-drugs that are very similar but not identical…”
Get full text

The roles of patents and research and development incentives in biopharmaceutical innovation by Grabowski, Henry G, DiMasi, Joseph A, Long, Genia

“…Patents and other forms of intellectual property protection play essential roles in encouraging innovation in biopharmaceuticals. As part of the "21st Century…”
Get full text

The Cost of Drug Development by DiMasi, Joseph A, Grabowski, Henry G, Hansen, Ronald W

“…The Tufts Center for the Study of Drug Development designed the recent study of the costs of new drug research and development to capture only the costs…”
Get full text

The economic returns of pediatric clinical trials of antihypertensive drugs by Baker-Smith, Carissa M., MD, MS, Benjamin, Daniel K., MD, PhD, Grabowski, Henry G., PhD, Reid, Elizabeth D., BA, Mangum, Barry, PharmD, Goldsmith, John V., PhD, Murphy, M. Dianne, MD, Edwards, Rex, BS, Eisenstein, Eric L., DBA, Sun, Jessica, MD, Califf, Robert M., MD, Li, Jennifer S., MD, MHS

“…Background Congress has authorized the United States Food and Drug Administration (FDA) to provide industry sponsors with a 6-month extension of drug marketing…”
Get full text

Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act by Grabowski, Henry G., Vernon, John M.

“…As a result of the 1984 Drug Price Competition and Patent Term Restoration Act and related factors, the degree of generic competition experienced by major…”
Get full text

Generic competition and market exclusivity periods in pharmaceuticals by Grabowski, Henry G., Kyle, Margaret

“…In this paper we examine generic competition and market exclusivity periods for pharmaceuticals experiencing their initial generic entry between 1995 and 2005…”
Get full text

Developing Drugs For Developing Countries by Ridley, David B, Grabowski, Henry G, Moe, Jeffrey L

“…Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in…”
Get full text

Cost of innovation in the pharmaceutical industry by DiMasi, J A, Hansen, R W, Grabowski, H G, Lasagna, L

“…The research and development costs of 93 randomly selected new chemical entities (NCEs) were obtained from a survey of 12 U.S.-owned pharmaceutical firms…”
Get more information

Risk-based decision making and ethical considerations in donor compensation for plasma-derived medicinal products by Skinner, Mark W., Hedlund Hoppe, P. Ann, Grabowski, Henry G., Manning, Richard, Tachdjian, Raffi, Crone, James F., Youngner, Stuart J.

Get full text

Returns to R&D on new drug introductions in the 1980s by Grabowski, H G, Vernon, J M

“…This study finds that the mean IRR for 1980-84 U.S. new drug introductions is 11.1%, and the mean NPV is 22 million (1990 dollars). The distribution of returns…”
Get more information

TRENDS: The Quantity And Quality Of Worldwide New Drug Introductions, 1982-2003 by Grabowski, Henry G, Wang, Y Richard

“…We examined trends in the introduction of new chemical entities (NCEs) worldwide from 1982 through 2003. Although annual introductions of NCEs decreased over…”
Get full text

An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma Donors by Grabowski, Henry G., Manning, Richard L.

“…Human blood plasma and its derivative therapies have been used therapeutically for more than 50 years, after first being widely used to treat injuries during…”
Get full text

The Quantity And Quality Of Worldwide New Drug Introductions, 1982-2003 by Grabowski, Henry G, Wang, Y. Richard

“…We examined trends in the introduction of new chemical entities (NCEs) worldwide from 1982 through 2003. Although annual introductions of NCEs decreased over…”
Get full text

Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention by Grabowski, Henry G, Moe, Jeffrey L

“…Chemoprevention agents are an emerging new scientific area that holds out the promise of delaying or avoiding a number of common cancers. These new agents face…”
Get full text